316 related articles for article (PubMed ID: 34100218)
21. Regulation of the sodium/iodide symporter by retinoids--a review.
Schmutzler C
Exp Clin Endocrinol Diabetes; 2001; 109(1):41-4. PubMed ID: 11573138
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake.
Castro MR; Bergert ER; Goellner JR; Hay ID; Morris JC
J Clin Endocrinol Metab; 2001 Nov; 86(11):5627-32. PubMed ID: 11701745
[TBL] [Abstract][Full Text] [Related]
23. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism.
Filetti S; Bidart JM; Arturi F; Caillou B; Russo D; Schlumberger M
Eur J Endocrinol; 1999 Nov; 141(5):443-57. PubMed ID: 10576759
[TBL] [Abstract][Full Text] [Related]
24. Rat sodium iodide symporter allows using lower dose of 131I for cancer therapy.
Mitrofanova E; Unfer R; Vahanian N; Link C
Gene Ther; 2006 Jul; 13(13):1052-6. PubMed ID: 16525480
[TBL] [Abstract][Full Text] [Related]
25. Predictive role of nontumoral sodium iodide symporter activity and preoperative thyroid characteristics in remission process of thyroid cancer patients.
Yildirim-Poyraz N; Yazgan A; Ozdemir E; Gozalan A; Keskin M; Ersoy R; Turkolmez S; Cakir B
Ann Nucl Med; 2014 Aug; 28(7):623-31. PubMed ID: 24823701
[TBL] [Abstract][Full Text] [Related]
26. Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy.
Liu Y; Wang J; Hu X; Pan Z; Xu T; Xu J; Jiang L; Huang P; Zhang Y; Ge M
Drug Resist Updat; 2023 May; 68():100939. PubMed ID: 36806005
[TBL] [Abstract][Full Text] [Related]
27. Manipulation of PBF/PTTG1IP phosphorylation status; a potential new therapeutic strategy for improving radioiodine uptake in thyroid and other tumors.
Smith VE; Sharma N; Watkins RJ; Read ML; Ryan GA; Kwan PP; Martin A; Watkinson JC; Boelaert K; Franklyn JA; McCabe CJ
J Clin Endocrinol Metab; 2013 Jul; 98(7):2876-86. PubMed ID: 23678037
[TBL] [Abstract][Full Text] [Related]
28. Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma.
Schmohl KA; Dolp P; Schug C; Knoop K; Klutz K; Schwenk N; Bartenstein P; Nelson PJ; Ogris M; Wagner E; Spitzweg C
Thyroid; 2017 Dec; 27(12):1534-1543. PubMed ID: 29032724
[TBL] [Abstract][Full Text] [Related]
29. Modulation of sodium iodide symporter in thyroid cancer.
Lakshmanan A; Scarberry D; Shen DH; Jhiang SM
Horm Cancer; 2014 Dec; 5(6):363-73. PubMed ID: 25234361
[TBL] [Abstract][Full Text] [Related]
30. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
[TBL] [Abstract][Full Text] [Related]
31. The effect of sodium iodide symporter protein on ablation success in patients with differentiated thyroid cancer.
Mutevelızade G; Kocer NE; Reyhan M
Ann Nucl Med; 2022 Dec; 36(12):1050-1058. PubMed ID: 36214955
[TBL] [Abstract][Full Text] [Related]
32. A Carboxy-Terminal Monoleucine-Based Motif Participates in the Basolateral Targeting of the Na+/I- Symporter.
Martín M; Modenutti CP; Peyret V; Geysels RC; Darrouzet E; Pourcher T; Masini-Repiso AM; Martí MA; Carrasco N; Nicola JP
Endocrinology; 2019 Jan; 160(1):156-168. PubMed ID: 30496374
[TBL] [Abstract][Full Text] [Related]
33. Dimerization of the Sodium/Iodide Symporter.
Thompson RJ; Fletcher A; Brookes K; Nieto H; Alshahrani MM; Mueller JW; Fine NHF; Hodson DJ; Boelaert K; Read ML; Smith VE; McCabe CJ
Thyroid; 2019 Oct; 29(10):1485-1498. PubMed ID: 31310151
[No Abstract] [Full Text] [Related]
34. The Sodium/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications.
Ravera S; Reyna-Neyra A; Ferrandino G; Amzel LM; Carrasco N
Annu Rev Physiol; 2017 Feb; 79():261-289. PubMed ID: 28192058
[TBL] [Abstract][Full Text] [Related]
35. TESC promotes differentiated thyroid cancer development by activating ERK and weakening NIS and radioiodine uptake.
Guo Y; Cai Y; Song F; Zhu L; Hu Y; Liu Y; Ma W; Ge J; Zeng Q; Ding L; Li L; Zheng G; Ge M
Endocrine; 2023 Sep; 81(3):503-512. PubMed ID: 37020077
[TBL] [Abstract][Full Text] [Related]
36. The PDZ protein SCRIB regulates sodium/iodide symporter (NIS) expression at the basolateral plasma membrane.
Martín M; Salleron L; Peyret V; Geysels RC; Darrouzet E; Lindenthal S; Bernal Barquero CE; Masini-Repiso AM; Pourcher T; Nicola JP
FASEB J; 2021 Aug; 35(8):e21681. PubMed ID: 34196428
[TBL] [Abstract][Full Text] [Related]
37. Molecular basis and targeted therapies for radioiodine refractory thyroid cancer.
Yu Q; Zhang X; Li L; Zhang C; Huang J; Huang W
Asia Pac J Clin Oncol; 2023 Jun; 19(3):279-289. PubMed ID: 35950297
[TBL] [Abstract][Full Text] [Related]
38. Alpha-lipoic acid induces sodium iodide symporter expression in TPC-1 thyroid cancer cell line.
Choi HJ; Kim TY; Ruiz-Llorente S; Jeon MJ; Han JM; Kim WG; Shong YK; Kim WB
Nucl Med Biol; 2012 Nov; 39(8):1275-80. PubMed ID: 22995901
[TBL] [Abstract][Full Text] [Related]
39. Sodium iodide symporter: its role in nuclear medicine.
Chung JK
J Nucl Med; 2002 Sep; 43(9):1188-200. PubMed ID: 12215558
[TBL] [Abstract][Full Text] [Related]
40. [Therapy concepts for thyroid carcinoma].
Eilsberger F; Kreissl MC; Luster M; Pfestroff A
Nuklearmedizin; 2022 Jun; 61(3):223-230. PubMed ID: 34644802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
